Iwai, T.; Mishima, R.; Hirayama, S.; Nakajima, H.; Oyama, M.; Watanabe, S.; Fujii, H.; Tanabe, M.
SYK-623, a δ Opioid Receptor Inverse Agonist, Mitigates Chronic Stress-Induced Behavioral Abnormalities and Disrupted Neurogenesis. J. Clin. Med. 2024, 13, 608.
https://doi.org/10.3390/jcm13020608
AMA Style
Iwai T, Mishima R, Hirayama S, Nakajima H, Oyama M, Watanabe S, Fujii H, Tanabe M.
SYK-623, a δ Opioid Receptor Inverse Agonist, Mitigates Chronic Stress-Induced Behavioral Abnormalities and Disrupted Neurogenesis. Journal of Clinical Medicine. 2024; 13(2):608.
https://doi.org/10.3390/jcm13020608
Chicago/Turabian Style
Iwai, Takashi, Rei Mishima, Shigeto Hirayama, Honoka Nakajima, Misa Oyama, Shun Watanabe, Hideaki Fujii, and Mitsuo Tanabe.
2024. "SYK-623, a δ Opioid Receptor Inverse Agonist, Mitigates Chronic Stress-Induced Behavioral Abnormalities and Disrupted Neurogenesis" Journal of Clinical Medicine 13, no. 2: 608.
https://doi.org/10.3390/jcm13020608
APA Style
Iwai, T., Mishima, R., Hirayama, S., Nakajima, H., Oyama, M., Watanabe, S., Fujii, H., & Tanabe, M.
(2024). SYK-623, a δ Opioid Receptor Inverse Agonist, Mitigates Chronic Stress-Induced Behavioral Abnormalities and Disrupted Neurogenesis. Journal of Clinical Medicine, 13(2), 608.
https://doi.org/10.3390/jcm13020608
